CSF1 and neoplasm: Both the selective monocyte targeting chemotherapeutic agent, trabectedin, and colony-stimulating factor 1 (CSF1) inhibitor that targets TAM can inhibit the recruitment of macrophages to TME, resulting in reduced tumor growth and metastasis formation [94,95].